Fulltext

Concurrent chemoradiotherapy for T3-4 and N0-1 nasopharyngeal cancer: Asian multicenter trial of the Forum for Nuclear Cooperation in Asia

Ohno T 1 , Wakatsuki M 2 , Thinh DH 3 , Tung NT 4 , Erawati D 5 , Supriana N 6 Show all authors , Beena Devi CR 7 , Kato S 8 , Thephamongkhol K 9 , Chansilpa Y 9 , Calaguas MJ 10 , Xiaoting X 11 , Jianping C 11 , Banu PA 12 , Cho CK 13 , Karasawa K 14 , Nakano T 15 , Tsujii H 14

Affiliations 

  • 1 Gunma University Heavy Ion Medical Center, Gunma University, Gunma, Japan
  • 2 Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan masaru.wakatsuki@nifty.com
  • 3 Department of Radiation Oncology No. 3, Ho Chi Minh City Cancer Center, Ho Chi Minh City, Vietnam
  • 4 Head and Neck Radiation Department, National Cancer Hospital, Hanoi, Vietnam
  • 5 Department of Radiotherapy, Dr Soetomo General Hospital, Surabaya, Indonesia
  • 6 Department of Radiotherapy, Dr Cipto Mangunkusumo General Hospital, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia
  • 7 Department of Radiation Oncology, Sarawak General Hospital, Kuching, Malaysia
  • 8 Department of Radiation Oncology, Saitama Medical University International Medical Center, Saitama, Japan
  • 9 Department of Radiology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
  • 10 Department of Radiation Oncology, St Luke's Medical Center, Quezon City, Philippines
  • 11 Department of Radiation Oncology, The First Affiliated Hospital of Soochow University, Suzhou, China
  • 12 Department of Radiation Oncology, Delta Hospitals Limited, Dhaka, Bangladesh
  • 13 Department of Radiation Oncology, Korea Institute of Radiological and Medical Sciences, Seoul, Korea
  • 14 Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan
  • 15 Department of Radiation Oncology, Gunma University Graduate School of Medicine, Gunma, Japan
J Radiat Res, 2016 Jan;57(1):44-9.
PMID: 26254458 DOI: 10.1093/jrr/rrv046

Abstract

The aim of this study was to evaluate the toxicity and efficacy of radiotherapy concurrent with weekly cisplatin for T3-4 and N0-1 nasopharyngeal cancer. Between 2005 and 2010, 70 patients with nasopharyngeal cancer (T3-4 N0-1 M0, World Health Organization Type 2-3) from Vietnam, Indonesia, Malaysia and Thailand were registered. Patients were treated with 2D radiotherapy concurrent with weekly cisplatin (30 mg/m(2)). Neither adjuvant nor induction chemotherapy was given. Ninety-three percent of the patients completed at least four cycles of weekly cisplatin during radiotherapy. The median total doses for the primary tumor and positive lymph nodes were 70 and 66 Gy, respectively. The median overall treatment time of concurrent chemoradiotherapy was 52 days. No treatment-related deaths occurred. Grade 3-4 acute toxicities of mucositis, nausea/vomiting and leukopenia were observed in 34%, 4% and 4% of patients, respectively. With a median follow-up time of 52 months for the 40 surviving patients, the 3-year local control, locoregional tumor control, distant metastasis-free survival and overall survival rates were 80%, 75%, 74% and 80%, respectively. In conclusion, the current results illustrate that our concurrent chemoradiotherapy regimen was feasible, but disease control remained insufficient. Further research is encouraged in order to improve clinical outcomes.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications